Urethral cancer
Urethral cancer grows in the tube that carries urine out of the body. It is very rare, so doctors treat it by borrowing from bladder cancer, anal cancer and vulvar cancer depending on the cell type and location. Combining chemotherapy with radiotherapy before or instead of surgery lets more patients keep their organs.
Overview
Primary urethral carcinoma is defined by where in the urethra it starts and by the lining it arises from: urothelial carcinoma in the prostatic and proximal urethra, squamous cell carcinoma in the distal (penile or anterior) urethra, and adenocarcinoma, often of Skene or Littre gland origin or arising in a diverticulum, particularly in women. Risk factors include chronic stricture and inflammation, prior radiotherapy, urethral diverticulum and HPV infection for squamous tumours. Presentation is with bleeding, obstruction or a palpable mass, and diagnosis is frequently delayed because symptoms mimic stricture or infection.
There are no randomised trials. Distal tumours are treated with organ-sparing surgery (partial urethrectomy or distal penectomy in men; distal urethrectomy in women) or with radiotherapy; proximal and locally advanced tumours have historically required radical cystoprostatectomy or anterior exenteration, but the modern approach favours neoadjuvant or definitive platinum-based chemotherapy with or without radiotherapy, extrapolated from bladder cancer (cisplatin-based combinations for urothelial histology) and anal or vulvar cancer (mitomycin or cisplatin with fluorouracil and radiotherapy for squamous histology). Multi-institutional series such as those from the international collaboration on primary urethral carcinoma show better survival with multimodal therapy than with surgery alone, and the EAU has published a dedicated guideline.
The practical frontier is applying advances from urothelial cancer (enfortumab vedotin with pembrolizumab, checkpoint inhibitors) and HPV-associated squamous cancers to this tiny population through basket trials and registries.
State of the art today
- Multimodal therapy (chemotherapy with radiotherapy or surgery) has largely replaced radical surgery alone, based on international retrospective collaborations.
- Treatment is chosen by histology, borrowing the best evidence from bladder cancer for urothelial tumours and from anal and vulvar cancer for squamous tumours.
- The EAU maintains the only dedicated guideline; registries and basket trials are the path to better evidence.
Where it starts and where it drains
Renal cell carcinoma comes from the kidney's filtering cortex, urothelial cancer from the lining of the collecting system and bladder, and the adrenal on top hosts cortical and medullary (neuroblastoma) tumours.
- Renal cortex (RCC)Adenocarcinoma (including clear cell adenocarcinoma of the female urethra)
- Renal pelvis and ureter (upper tract urothelial)
- Bladder lining (non-muscle-invasive)Urothelial carcinoma (proximal and prostatic urethra) · Squamous cell carcinoma (distal urethra; HPV-associated in some) · Adenocarcinoma (including clear cell adenocarcinoma of the female urethra) · Urethral melanoma (very rare)
- Bladder muscle wall (muscle-invasive)Squamous cell carcinoma (distal urethra; HPV-associated in some)
- Adrenal cortex
- Adrenal medulla and sympathetic chain (neuroblastoma)
- Developing kidney (Wilms tumour)
- renal hilar
- para-aortic and paracaval
- obturator and iliac (bladder)
Same organ: Bladder & urothelial cancer, Renal cell carcinoma, Wilms tumour (nephroblastoma), Neuroblastoma (paediatric), Adrenocortical carcinoma, Pheochromocytoma and paraganglioma (PPGL), Penile cancer
One of the rarest genitourinary cancers, with fewer than one case per million per year in most registries; it is more common in men and in people over 60.
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- High-risk pancreatic surveillance (CAPS / PRECEDE)Established
- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Where the cases are
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy.
Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative.
Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials.
Subtypes & biomarkers
top- Urothelial carcinoma (proximal and prostatic urethra)
- Squamous cell carcinoma (distal urethra; HPV-associated in some)
- Adenocarcinoma (including clear cell adenocarcinoma of the female urethra)
- Urethral melanoma (very rare)
- Histology and site (drives treatment analogy)
- Clinical and MRI stage, nodal status
- HPV / p16 in squamous tumours
- PD-L1 and FGFR3 in urothelial histology (extrapolated from bladder cancer)
- Urine cytology and urethroscopy findings
Target prevalence in this cancer
- 1834First reported case of urethral carcinoma
Thiaudierre's description in a woman.
- 2013International collaboration on primary urethral carcinoma
Gakis and colleagues pool multi-institutional data, showing benefit of perioperative chemotherapy and defining the EAU guideline.
- 2023Enfortumab vedotin plus pembrolizumab approved for urothelial cancer
Applied by extrapolation to urothelial-type urethral carcinoma.
Open problems, and what is being done about each
No prospective trials; international registries and inclusion in urothelial and HPV-squamous basket trials are the response.
Late diagnosis mimicking benign stricture; urethroscopy for unexplained stricture or bleeding is the practical fix.
and how the field plans to fix it →What is being done about thisFinding cancer earlierAvailable now- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- High-risk pancreatic surveillance (CAPS / PRECEDE)Established
In trialsIdeas and roadmaps- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Balancing organ preservation with cure in proximal tumours; chemoradiation series are growing.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Expert centres
topCentres linked to this cancer in OnCo
- Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer CenterBaltimore, USNewsweek oncology #10NCI comprehensivevia Pembrolizumab
- American Society for Radiation OncologyArlington, VA, USvia Brachytherapy, IMRT / IGRT (modern external beam)
- Centre Oscar LambretLille, FRvia Brachytherapy, IMRT / IGRT (modern external beam)
- European Society for Radiotherapy and OncologyBrussels, BEvia Brachytherapy, IMRT / IGRT (modern external beam)
- Groote Schuur Hospital / University of Cape TownCape Town, ZAvia Brachytherapy, IMRT / IGRT (modern external beam)
- Hacettepe University Cancer InstituteAnkara, TRvia Brachytherapy, IMRT / IGRT (modern external beam)
- Ho Chi Minh City Oncology HospitalHo Chi Minh City, VNvia Brachytherapy, IMRT / IGRT (modern external beam)
- Institut BergoniéBordeaux, FRvia Brachytherapy, IMRT / IGRT (modern external beam)
- Institut National d'Oncologie, RabatRabat, MAvia Brachytherapy, IMRT / IGRT (modern external beam)
- Institut Salah AzaïezTunis, TNvia Brachytherapy, IMRT / IGRT (modern external beam)
- Institute of Oncology LjubljanaLjubljana, SIvia Brachytherapy, IMRT / IGRT (modern external beam)
- via Brachytherapy, IMRT / IGRT (modern external beam)
- Istanbul University Institute of OncologyIstanbul, TRvia Brachytherapy, IMRT / IGRT (modern external beam)
- Kenyatta National HospitalNairobi, KEvia Brachytherapy, IMRT / IGRT (modern external beam)
- Korle Bu Teaching HospitalAccra, GHvia Brachytherapy, IMRT / IGRT (modern external beam)
- Lagos University Teaching HospitalLagos, NGvia Brachytherapy, IMRT / IGRT (modern external beam)
- via Brachytherapy, IMRT / IGRT (modern external beam)
- via Brachytherapy, IMRT / IGRT (modern external beam)
- National Institute of Oncology, HungaryBudapest, HUvia Brachytherapy, IMRT / IGRT (modern external beam)
- Ocean Road Cancer InstituteDar es Salaam, TZvia Brachytherapy, IMRT / IGRT (modern external beam)
- Velindre Cancer CentreCardiff, GBvia Brachytherapy, IMRT / IGRT (modern external beam)
- Aarhus University HospitalAarhus, DKvia IMRT / IGRT (modern external beam)
- Alliance for Clinical Trials in OncologyChicago, IL, USvia Pembrolizumab
- Cancer Institute (WIA), AdyarChennai, INvia Brachytherapy
- Centre Antoine LacassagneNice, FRvia IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- Comprehensive Cancer Center Freiburg (CCCF)Freiburg im Breisgau, DEvia IMRT / IGRT (modern external beam)
- Dharmais National Cancer CenterJakarta, IDvia Brachytherapy
- via Brachytherapy
- Geneva University Hospitals (HUG)Geneva, CHvia IMRT / IGRT (modern external beam)
- GOG FoundationPhiladelphia, PA, USvia Pembrolizumab
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- Hokkaido University HospitalSapporo, JPvia IMRT / IGRT (modern external beam)
- Hunan Cancer HospitalChangsha, CNvia IMRT / IGRT (modern external beam)
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, IN, USNCI comprehensivevia Cisplatin
- Institut Jules BordetBrussels, BEvia Pembrolizumab
- via Brachytherapy
- Instituto Nacional de Cancerología (Mexico)Mexico City, MXvia Brachytherapy
- via Brachytherapy
- via IMRT / IGRT (modern external beam)
- via Brachytherapy
- International Extranodal Lymphoma Study GroupBellinzona, CHvia IMRT / IGRT (modern external beam)
- IRCCS Humanitas Research HospitalRozzano (Milan), ITvia IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- Juravinski Cancer Centre / Escarpment Cancer Research InstituteHamilton, ON, CAvia IMRT / IGRT (modern external beam)
- Koo Foundation Sun Yat-Sen Cancer CenterTaipei, TWvia Brachytherapy
- via Pembrolizumab
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- via Brachytherapy
- Rajiv Gandhi Cancer Institute and Research CentreNew Delhi, INvia IMRT / IGRT (modern external beam)
- Rambam Health Care CampusHaifa, ILvia IMRT / IGRT (modern external beam)
- Rigshospitalet – Copenhagen University HospitalCopenhagen, DKvia IMRT / IGRT (modern external beam)
- Royal Adelaide HospitalAdelaide, AUvia IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- Siriraj Hospital, Mahidol UniversityBangkok, THvia IMRT / IGRT (modern external beam)
- Sunnybrook Odette Cancer CentreToronto, ON, CAvia Brachytherapy
- Tata Medical Center, KolkataKolkata, INvia IMRT / IGRT (modern external beam)
- Tawam HospitalAl Ain, AEvia IMRT / IGRT (modern external beam)
- Tel Aviv Sourasky Medical CenterTel Aviv, ILvia IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- TROG Cancer ResearchNewcastle, NSW, AUvia IMRT / IGRT (modern external beam)
- Uganda Cancer InstituteKampala, UGvia Brachytherapy
- UMC Utrecht Cancer CenterUtrecht, NLvia IMRT / IGRT (modern external beam)
- University of Malaya Medical CentreKuala Lumpur, MYvia IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- via IMRT / IGRT (modern external beam)
- Zhejiang Cancer HospitalHangzhou, CNvia IMRT / IGRT (modern external beam)
Questions to ask
topQuestions to ask your oncologist about Urethral cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Histology and site, Clinical and MRI stage, nodal status, HPV / p16 in squamous tumours, PD-L1 and FGFR3 in urothelial histology, Urine cytology and urethroscopy findings), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Urothelial carcinoma, Squamous cell carcinoma, Adenocarcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Distal, localised
- For my situation (distal, localised), which of the standard options do you recommend and why?Why: Guideline options include: Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy.
Proximal or locally advanced
- For my situation (proximal or locally advanced), which of the standard options do you recommend and why?Why: Guideline options include: Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative.
- Am I a candidate for Cisplatin, Gemcitabine + cisplatin, Fluorouracil (5-FU) or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Metastatic
- For my situation (metastatic), which of the standard options do you recommend and why?Why: Guideline options include: Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials.
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, Gemcitabine + cisplatin, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Enfortumab vedotin, Pembrolizumab?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No prospective trials; international registries and inclusion in urothelial and HPV-squamous basket trials are the response”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Late diagnosis mimicking benign stricture; urethroscopy for unexplained stricture or bleeding is the practical fix”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
8targets
2drugs
6companies
3pathways
1terms
3bottlenecks
1Latest papers
topQuery for this cancer: (TITLE:"Urethral cancer" OR ABSTRACT:"Urethral cancer" OR TITLE:"Primary urethral carcinoma" OR ABSTRACT:"Primary urethral carcinoma" OR TITLE:"Carcinoma of the urethra" OR ABSTRACT:"Carcinoma of the urethra") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Urethral cancer, not a curated reading list.
Pages like this
not linked directly; found by shared links- CancerVaginal cancer
Shares HPV-positive (p16) head and neck cancer, Chemoradiation (chemoradiotherapy, CRT), Fluorouracil (5-FU), Vulvar cancer and the tags nci-coverage, rare.
- CancerNasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)
Shares Cisplatin, Rare and paediatric cancers without markets, IMRT / IGRT (modern external beam), Cytotoxic chemotherapy and the tags nci-coverage, rare.
- CancerSmall intestine cancer (small bowel adenocarcinoma)
Shares Rare and paediatric cancers without markets, Cytotoxic chemotherapy, Pembrolizumab, PD-1 and the tags nci-coverage, rare.
- CancerEpithelioid sarcoma
Shares Rare and paediatric cancers without markets, IMRT / IGRT (modern external beam), Cytotoxic chemotherapy and the tags nci-coverage, rare.
- CancerParathyroid carcinoma
Shares Rare and paediatric cancers without markets, Immune checkpoint inhibitors and the tags nci-coverage, rare.
- CancerNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
Shares Cisplatin, Rare and paediatric cancers without markets, IMRT / IGRT (modern external beam), Cytotoxic chemotherapy and the tags nci-coverage, rare.
- CancerAmpullary cancer (ampulla of Vater)
Shares Rare and paediatric cancers without markets, Cytotoxic chemotherapy, Pembrolizumab and the tags nci-coverage, rare.
- CancerVascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)
Shares Rare and paediatric cancers without markets, IMRT / IGRT (modern external beam), Cytotoxic chemotherapy, PD-1 and the tags nci-coverage, rare.